HUE046590T2 - Eljárás máj eredetû enkefalopátia kezelésére - Google Patents

Eljárás máj eredetû enkefalopátia kezelésére

Info

Publication number
HUE046590T2
HUE046590T2 HUE17742782A HUE17742782A HUE046590T2 HU E046590 T2 HUE046590 T2 HU E046590T2 HU E17742782 A HUE17742782 A HU E17742782A HU E17742782 A HUE17742782 A HU E17742782A HU E046590 T2 HUE046590 T2 HU E046590T2
Authority
HU
Hungary
Prior art keywords
hepatic encephalopathy
treating hepatic
treating
encephalopathy
hepatic
Prior art date
Application number
HUE17742782A
Other languages
English (en)
Hungarian (hu)
Inventor
Frederic Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of HUE046590T2 publication Critical patent/HUE046590T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE17742782A 2016-07-29 2017-07-28 Eljárás máj eredetû enkefalopátia kezelésére HUE046590T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (en) 2016-07-29 2016-07-29 Method for treating hepatic encephalopathy

Publications (1)

Publication Number Publication Date
HUE046590T2 true HUE046590T2 (hu) 2020-03-30

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17742782A HUE046590T2 (hu) 2016-07-29 2017-07-28 Eljárás máj eredetû enkefalopátia kezelésére

Country Status (24)

Country Link
US (2) US10117854B2 (OSRAM)
EP (2) EP3275439A1 (OSRAM)
JP (1) JP2019522030A (OSRAM)
KR (1) KR20190034550A (OSRAM)
AU (1) AU2017303346A1 (OSRAM)
BR (1) BR112019001178A2 (OSRAM)
CA (1) CA3031302A1 (OSRAM)
CY (1) CY1122348T1 (OSRAM)
DK (1) DK3319601T3 (OSRAM)
EA (1) EA201990413A1 (OSRAM)
ES (1) ES2751154T3 (OSRAM)
HK (1) HK1254833B (OSRAM)
HR (1) HRP20191798T1 (OSRAM)
HU (1) HUE046590T2 (OSRAM)
IL (1) IL264460B (OSRAM)
LT (1) LT3319601T (OSRAM)
MA (1) MA42419B1 (OSRAM)
ME (1) ME03520B (OSRAM)
PL (1) PL3319601T3 (OSRAM)
PT (1) PT3319601T (OSRAM)
RS (1) RS59300B1 (OSRAM)
SI (1) SI3319601T1 (OSRAM)
SM (1) SMT201900628T1 (OSRAM)
WO (1) WO2018020010A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
CN116173182A (zh) * 2023-03-31 2023-05-30 苏州融析生物科技有限公司 醋酸格拉替雷药物组合物在肝硬化预防及治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy

Also Published As

Publication number Publication date
EA201990413A1 (ru) 2019-06-28
MA42419A (fr) 2018-05-16
US20180214417A1 (en) 2018-08-02
PL3319601T3 (pl) 2020-06-29
MA42419B1 (fr) 2019-11-29
IL264460B (en) 2021-06-30
DK3319601T3 (da) 2019-11-18
EP3275439A1 (en) 2018-01-31
BR112019001178A2 (pt) 2019-04-30
US20190070150A1 (en) 2019-03-07
CA3031302A1 (en) 2018-02-01
WO2018020010A1 (en) 2018-02-01
HK1254833B (en) 2020-05-22
JP2019522030A (ja) 2019-08-08
CY1122348T1 (el) 2021-01-27
RS59300B1 (sr) 2019-10-31
ES2751154T3 (es) 2020-03-30
EP3319601A1 (en) 2018-05-16
LT3319601T (lt) 2019-11-11
SMT201900628T1 (it) 2020-01-14
US10117854B2 (en) 2018-11-06
KR20190034550A (ko) 2019-04-02
PT3319601T (pt) 2019-09-18
HRP20191798T1 (hr) 2019-12-27
EP3319601B1 (en) 2019-08-28
US10328059B2 (en) 2019-06-25
AU2017303346A1 (en) 2019-01-31
ME03520B (me) 2020-04-20
IL264460A (en) 2019-02-28
SI3319601T1 (sl) 2019-11-29

Similar Documents

Publication Publication Date Title
EP3564866A4 (en) CALCULATION PROCESS
EP3390273A4 (en) MICROSTRUCTURED SURFACE
BR112017003966A2 (pt) aparelhos e métodos para a produção simultânea de compostos canabinoides
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
HUE048265T2 (hu) Eljárás PD-L1 mennyiségi meghatározására
IL260413B1 (en) Method of treating influenza a
IL263050B (en) Derivatives of sobetirome
DK3341479T3 (da) LNA-G-Proces
BR112016023582A2 (pt) método de tratamento de um material
HUE043057T2 (hu) Eljárás lenyomatos biztonsági jellemzõ készítésére
PL3393468T3 (pl) Metody leczenia niedoboru odporności
DK3283210T3 (da) Fremgangsmåde
DK3318115T3 (da) Maskine til behandling af svinegylle
HRP20190251T1 (hr) Steroidni spoj za upotrebu za liječenje jetrene encefalopatije
DK3156539T3 (da) Kontinuerlig fremgangsmåde til forbehandling af et ligno-celluloseholdigt råmateriale
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
BR112016028188A2 (pt) embalagens e método de fabricação da mesma
EP3804841C0 (de) Verfahren mit elektrosorption
HUE056178T2 (hu) Módszer gombafertõzések kezelésére
PL3169844T3 (pl) Sposób zapobiegania tworzeniu się kamienia kotłowego
EP3532057A4 (en) KALLICREIN INHIBITOR PRODUCTS
DK3512846T3 (da) Ketonhæmmere af lysin-gingipain
HUE046590T2 (hu) Eljárás máj eredetû enkefalopátia kezelésére
EP3558903A4 (en) METHOD
EP3523659C0 (en) MULTI-PROTEASE PROCESS